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Introduction and objectives. The use of aspirin and 
non-aspirin analgesics have been associated with changes 
in blood pressure. The aim of this study was to investigate 
prospectively the association between the regular use of 
aspirin and non-aspirin analgesics and the incidence of 
hypertension.
Methods. The SUN project is an ongoing, continuously 
expanding, prospective cohort of Spanish university 
graduates initially free of hypertension, cardiovascular 
disease, diabetes, and cancer; 9986 (mean age, 36 years) 
were recruited during 1999–2005 and followed up for a 
mean of 51 months. Regular aspirin and non-aspirin 
analgesic use and the presence of other risk factors for 
hypertension were assessed by questionnaire at baseline, 
and the incidence of hypertension was assessed using 
biennial follow-up questionnaires.
Results. In total, 543 new cases of hypertension were 
identified during follow-up. Regular aspirin use (ie, ≥2 days/
week) was associated with a higher risk of hypertension 
(hazard ratio = 1.45; 95% confidence interval, 1.02–2.04) 
after adjustment for various confounding factors. Regular 
use of non-aspirin analgesic drugs was also associated 
with a higher risk of hypertension (hazard ratio = 1.69; 
95% confidence interval, 1.28–2.23).
Conclusions. The regular use of aspirin and non-aspirin 
analgesics were both associated with an increased risk 
of developing hypertension, independently of other risk 
factors.
Key words: Hypertension. Analgesics. Aspirin. SUN 
project. Cohorts.
Aspirina, analgésicos y riesgo de hipertensión 
arterial en la Cohorte SUN
Introducción y objetivos. Se ha relacionado el consumo 
de aspirina y de otros analgésicos con cambios en la pre-
sión arterial. El objetivo de nuestro estudio fue valorar pros-
pectivamente la asociación del uso habitual de aspirina y 
otros analgésicos con la incidencia de hipertensión arterial.
Métodos. El proyecto SUN es una cohorte prospectiva 
y dinámica que incluyó a 9.986 graduados universitarios 
españoles inicialmente libres de hipertensión, enferme-
dad cardiovascular, diabetes o cáncer (media de edad, 
36 años). Fueron reclutados durante el periodo 1999-
2005 y se los siguió prospectivamente durante una media 
de 51 meses. El uso habitual de aspirina y otros analgési-
cos, así como la presencia de otros factores de riesgo de 
hipertensión arterial, se valoró mediante un cuestionario 
basal. La incidencia de hipertensión se valoró con cues-
tionarios de seguimiento bienales.
Resultados. Durante el seguimiento se identificaron 
543 casos nuevos de hipertensión arterial. El uso habitual 
de aspirina (2 o más días/semana) se asoció con un ma-
yor riesgo de hipertensión (hazard ratio [HR] = 1,45; inter-
valo de confianza [IC] del 95%, 1,02-2,04) tras ajustar por 
diversos factores de confusión. El uso habitual de otros 
analgésicos diferentes de la aspirina también se asoció 
a un mayor riesgo de hipertensión arterial (HR = 1,69; IC 
del 95%, 1,28-2,23).
Conclusiones. El uso habitual tanto de aspirina como 
de otros analgésicos diferentes a la aspirina parece aso-
ciarse a mayor riesgo de hipertensión arterial, indepen-
dientemente de otros factores de riesgo. 
Palabras clave: Hipertensión arterial. Analgésicos. 
Aspirina. Proyecto SUN. Cohortes.
See editorial on pages 265-7
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baseline questionnaire gathered information on 
sociodemographic variables, lifestyle, including 
diet and physical activity, and medical information. 
Because of the dynamic cohort design, enrollment 
of participants is continuously open. The study 
protocol has been approved by the Institutional 
Review Board of the University of Navarra. The 
response to the initial questionnaire was considered 
as an informed consent to participate in the study.
Follow-up of the SUN participants is made 
through biennial mailed questionnaires collecting 
information about changes in lifestyles and risk 
factors, and presence of medical conditions. Up to 
5 mailings are sent to non-respondents. In January 
2008, the SUN cohort included 18 922 participants 
who had answered the baseline questionnaire. For 
this analysis we considered 15 222 individuals who 
answered the baseline questionnaire before January 
22, 2005 and had the chance to complete at least 
the first follow-up questionnaire. A total of 13 563 
participants had answered one of the follow up 
questionnaires (retention rate, 89%). From these, we 
excluded 1503 participants qualified as prevalent cases 
of HTN (defined as a self-reported medical diagnosis 
of HTN, use of antihypertensive medication, self-
reported systolic BP >140 mm Hg or diastolic BP 
>90 mm Hg in the baseline questionnaire), and 
1273 as prevalent cases of cardiovascular disease, 
diabetes, or cancer. In addition, 1214 had extreme 
caloric intake (total energy intake >4200 kcal/d 
or <800 kcal/d for men, or >3500 kcal/d or <500 
kcal/d for women) and 272 had missing information 
in any of the covariates used in the analysis. After 
applying the previous criteria, we excluded a total 
of 3577 participants. Thus, 9986 participants were 
considered for analyses.
Assessment of Exposure
At baseline, participants were asked whether 
they usually took aspirin at least 2 days a week and 
whether they usually took analgesic drugs other 
than aspirin. 
Assessment of Incident Hypertension
In the follow-up questionnaires participants 
were asked whether they had received a medical 
diagnosis of HTN in the time after they completed 
the previous questionnaire. The date (month and 
year) of the diagnosis was also requested. Incident 
cases of HTN were defined as those individuals self-
reporting a medical diagnosis of HTN in any of the 
follow-up questionnaires who did not have HTN at 
baseline. We have observed an acceptable validity 
of the self-reported diagnosis of HTN among our 
highly educated cohort, comparing it with objective 
INTRODUCTION
Hypertension (HTN) is a major risk factor 
for cardiovascular disease.1,2 Small increases of 
blood pressure (BP) have relevant and significant 
effect on morbidity and mortality.3 Aspirin and 
other analgesics like acetaminophen and other 
non steroidal anti-inflammatory drugs (NSAIDs) 
are widely used worldwide and could increase the 
BP levels through prostaglandins inhibition, and 
through sodium retention in the case of NSAIDs.4
Results from different prospective studies 
conducted in the United States assessing the 
association between use of aspirin, NSAIDs and 
other analgesics and the risk of hypertension 
suggest that chronic users of aspirin, NSAIDS, and 
acetaminophen have a higher risk of hypertension.5-9 
However, some clinical trials conducted in Spain 
have shown the opposite effect10,11 and no previous 
prospective study has assessed this potential 
relationship in a European cohort, where a different 
health system probably means different access to 
medication and a different pattern of drug use.12
Our objective was to assess the association between 
regular use of aspirin and non-aspirin analgesic drugs 
and the incidence of HTN in a prospective dynamic 
cohort study consisting of Spanish university 
graduates, the SUN (Seguimiento Universidad de 
Navarra, University of Navarra Follow-up) project.
METHODS
The SUN project is a dynamic cohort of university 
graduates in Spain. The objectives and methods 
of the SUN cohort have been reported with detail 
elsewhere.13,14 Briefly, beginning in December 1999 
a letter of invitation and a mailed questionnaire 
was sent to all alumni of the University of Navarra 
and other university graduates living in Spain. The 
ABBREVIATIONS







NSAID: non-steroidal anti-inflammatory drug
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population. The model containing all these variables 
will be subsequently referred to as the multivariable 
Cox regression model. To test for the existence 
of confounding by indication, we conducted an 
additional analysis adjusting for a diagnosis of 
rheumatoid arthritis, gastric ulcer or headache at 
baseline.
We repeated the analyses after stratifying by 
gender, age and BMI in order to assess potential 
effect modification (interaction) by these variables, 
and formally tested the interactions introducing 
product-terms in the multivariable Cox regression 
models. 
RESULTS
At baseline, the mean age of the 9986 participants 
included in the analyses was 36 years. During the 
follow-up period (mean, 51 months), we observed 
543 incident cases of hypertension. The distribution 
of potential confounding variables according to 
aspirin and non-aspirin analgesic use is displayed in 
Table 1. Regular use of aspirin was associated with 
being male, older, smoker, having a higher BMI, 
not engaging in leisure-time physical activities, 
drinking more alcohol, and presenting higher intake 
of sodium, fruits, and vegetables. Regular use of 
non-aspirin analgesic drugs was associated with 
being female, not engaging in leisure-time physical 
activities, taking less alcohol, more vegetables and 
low-fat dairy, and having more family history of 
hypertension. 
Aspirin regular use was significantly associated 
with incident hypertension (HR = 1.45; 95% CI, 
1.02-2.04) after adjustment for multiple potential 
confounders (Table 2). Use of non-aspirin analgesic 
drugs (other analgesic drugs) was also associated 
with incident hypertension both before and after 
adjustment for multiple potential confounders (HR 
= 1.69; 95% CI, 1.28-2.23) (Table 2). We repeated 
the analyses including simultaneously aspirin and 
other analgesic drugs use in the model. Results did 
not appreciably change and are displayed in Table 
2. Finally, Table 3 reports analyses stratified by 
sex. Association estimates had wider confidence 
intervals. Results were similar for people younger or 
older than 34.5 years (median), younger and older 
than 45 years, and for normoweight and overweight 
participants (data not shown). Results were also 
similar when adjusting for total energy intake and 
for consumption of the following items, first as 
continuous and then as quintiles: red meat, total 
fat, mono-unsaturated fat, poli-unsaturated fat, and 
saturated fat (results not shown).
There was no evidence of any potential statistical 
interaction. Specifically, interaction terms for age 
and aspirin or other analgesic drugs use were P=.16 
measurements of BP in a random subsample of the 
cohort.15,16
Assessment of Covariates
The baseline questionnaire requested additional 
information about a wide array of sociodemographic 
factors (sex, age, university degree, marital and 
employment status), anthropometric measurements 
(weight, height), health-related habits (diet, 
smoking status, alcohol consumption, and physical 
activity), and clinical variables (use of medication, 
personal and family history of hypertension, 
hypercholesterolemia, coronary heart disease, 
cancer, and other diseases). We calculated the body 
mass index (BMI) using the self-reported weight in 
kilograms divided by the square of height in meters. 
The amount of physical activity during leisure time 
was quantified from an activity metabolic equivalent 
(MET) index, computed by assigning a multiple of 
resting metabolic rate (MET score) to each of 17 
activities included in the baseline questionnaire.17 
Time spent in each of the activities was multiplied 
by the MET score specific to each activity. Then, 
the value of overall weekly MET-hours activity 
was obtained from the sum of all activities. The 
validity of self reported weight and leisure-time 
physical activity has been demonstrated in the SUN 
cohort.18,19 Dietary habits were assessed using a semi-
quantitative food-frequency questionnaire with 136 
items, previously validated in Spain.20
Statistical Analysis
We estimated hazard ratios (HR) and their 95% 
confidence interval (CI) for the risk of incident 
hypertension according to the regular use of aspirin 
and non-aspirin analgesic drugs using a multivariable 
Cox regression analysis. Time of follow-up was 
defined as the time elapsed from the completion of 
the baseline questionnaire to the diagnosis of HTN 
or the date of the last follow-up questionnaire, 
whichever came earlier. We ran age (continuous) 
and sex-adjusted models and an additional model 
adjusting for the following variables: sex (binary), 
age (continuous), baseline BMI (continuous), 
leisure-time physical activity (total METs as 
continuous), alcohol intake (continuous), family 
history of hypertension (binary), self-reported 
hypercholesterolemia (binary), smoking (current 
and past smokers vs never smokers), energy adjusted 
sodium intake, olive oil, fruit, vegetable, and low-
fat dairy consumption (all of them in quartiles). 
Some of these variables were selected as well known 
risk factors for hypertension; others were selected 
because they have shown to be associated with 
hypertension in previous studies done in this same 
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0.95-5.61) when compared to non-users. Finally, to 
control for potential confounding by indication, we 
repeated the analyses including the baseline diagnosis 
of rheumatoid arthritis, gastric ulcers, and headache, 
observing similar results (data not shown).
DISCUSSION
In this analysis of the SUN project, we have 
observed that regular use of both aspirin and non-
aspirin analgesic drugs could be associated with a 
higher risk of incident HTN independently of other 
risk factors. 
and P=.97 respectively, for BMI  were P=.76 and 
P=.59 respectively, and finally for gender were 
P=.63 and P=.30 respectively.
A total of 47 participants took both aspirin 
and other analgesic drugs. Results did not change 
significantly after excluding them (HR = 1.45; 95% 
CI, 1.02-2.04 for aspirin and HR = 1.69; 95% CI, 
1.28-2.23 for other analgesic drugs). In addition, 
we created a new variable including 4 categories 
(non-users, aspirin users, other analgesic drugs 
users, and both aspirin and other analgesic drugs 
users). Participants who took both aspirin and other 
analgesic drugs presented a HR = 2.31 (95% CI, 
TABLE 1. Distribution of Potential Confounding Variables According to Baseline Regular Aspirin and Non-Aspirin 
Analgesic Use in the SUN Study, 1999-2005
 Aspirin Non-Aspirin Analgesic Drugs
 Yes No Yes No
Participants, n 333 9653 798 9188
Male, % 45.9 38.3 22.3 40
Age, mean, y 41.26 36.18 35.31 36.44
BMI, mean, kg/m2 23.8 23.1 23 23.1
Physical activity, mean, METS-h/wk 22.4 24.5 21.3 24.7
Smoker, %a 64 50 54 50
Alcohol intake, mean, g/d 8 6 5 6
Family history of hypertension, % 37 38 41 38
Sodium intake, mean, g/d 4.4 4 4.3 4
Hypercholesterolemia, self-reported, % 14 14 14 14
Fruits intake, mean, g/d 367 329 337 329
Vegetables intake, mean, g/d 556 504 542 503
Olive oil intake, mean, g/d 17 18 19 18
Low-fat dairy intake, mean, g/d 207 215 268 210
BMI indicates body mass index; MET, metabolic equivalent.
aCurrent and past smokers.
TABLE 2. HR (95% CI) of Self-Reported Hypertension According to Baseline Regular Aspirin and Non-Aspirin 
Analgesic Drugs Regular Use in the SUN Study, 1999-2005
 No  Yes Total
Aspirin   
 New cases of HTN, n 507 36 543
 Person-years, n 40 529 1404 41 933
 Age and sex adjusted, HR (95% CI) 1 (Ref) 1.35 (0.96-1.90) 
 Multivariate 1, HRa (95% CI) 1 (Ref) 1.45 (1.03-2.05) 
 Multivariate 2, HRb (95% CI) 1 (Ref) 1.42 (1.00-2.00) 
Non-aspirin analgesis use   
 New cases of HTN, n 486 57 543
 Person-years, n 38 679 3255 41 933
 Age and sex adjusted, HR (95% CI) 1 (Ref) 1.58 (1.21-2.05) 
 Multivariate 1, HRa (95% CI) 1 (Ref) 1.69 (1.28-2.23) 
 Multivariate 2, HRc (95% IC) 1 (Ref) 1.67 (1.26-2.21) 
CI indicates confidence interval; HR, hazard ratio; HTN, hypertension.
aAnalysis adjusted for sex, age (continous), baseline BMI (continuous), leisure-time physical activity (total METs as continuous), alcohol intake (continuous), family history 
of hypertension (binary), self-reported hypercholesterolemia (binary), smoking (current and past smokers vs never smokers), energy adjusted sodium (quartiles), olive oil 
(quartiles), fruit (quartiles), vegetable (quartiles), and low-fat dairy consumption (quartiles).
bSame as multivariate 1 plus adjustment for non-aspirin analgesic drugs use.
cSame as multivariate 1 plus adjustment for aspirin use.
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RR = 1.16; 95% CI, 0.92-1.48; acetaminophen, RR 
= 1.08; 95% CI, 0.87-1.58; NSAIDs, RR = 1.05; 95% 
CI, 0.89-1.24).9 However, 96% of the participants 
were habitual aspirin users (daily 235 mg of aspirin) 
and this homogeneous distribution of the assessed 
exposure may have reduced the power of the study 
to detect a small to moderately elevated risk of HTN 
due to aspirin intake.9 Finally, analyses from the 
Health Professionals Follow-up Study assessed the 
association between NSAID consumption (6-7 days 
per week vs none) and self-reported hypertension.7 
They found an adjusted RR = 1.26 (95% CI, 1.14-
1.40; P<.001 for trend) for aspirin, RR = 1.34 (95% 
CI, 1.00-1.79; P<.01 for trend) for acetaminophen, 
and RR = 1.38 (95% CI, 1.09-1.75; P<.002 for trend) 
for NSAIDs.7
Some trials have also assessed the association 
between analgesic use and BP changes. In 
relation to the use of aspirin, the Hypertension 
Optimal Treatment Study (HOT) analyzed 18 790 
hypertensive patients in an age range of 50 to 80 
years, with mean follow up 3.8 years. They compared 
aspirin (75 mg/day) versus placebo. BP in the aspirin 
group was 0.6/0.3 mm Hg higher than in the control 
group, suggesting a positive association. However, 
these BP changes were clinically irrelevant when 
compared to the BP changes attributed to the anti-
Previous prospective epidemiological studies 
have assessed the association between aspirin, 
acetaminophen, or NSAID use and incident 
hypertension. Analyses from the Nurses’ Health 
Study (NSH) comparing the highest (>22 days/month) 
with the lowest (none) exposure group found that 
increased frequency of use of aspirin, acetaminophen, 
or NSAIDs, was associated with an increased risk 
of self reported physician-diagnosed HTN (aspirin, 
RR = 1.21; 95% CI, 1.13-1.30; acetaminophen, RR 
= 1.20; 95% CI, 1.08-1.33; NSAIDs, RR = 1.35; 95% 
CI, 1.25-1.46).6 A later analysis of the NHS II found 
similar results for acetaminophen (RR = 2; 95% CI, 
1.52-2.62) and for NSAIDs (RR = 1.86; 95% CI, 
1.51-2.28), but no significant association was found 
for aspirin.5 However, the mean age in this second 
analysis was lower (range, 31-50) than in the first 
one (range, 49-61). Finally, other analyses including 
selected participants from both the NHS and NHS 
II together did not find a global association for 
aspirin (RR = 1.12; 95% CI, 0.67-1.86 among older 
women and RR = 1.35; 95% CI, 0.84-2.18 among 
younger women) but they detected a marginal 
association only among younger women (P for 
trend .06).8 Results from cumulative analgesic use 
for 14 years in the Physicians’ Health Study did not 
find significant results for any of the drugs (aspirin, 
TABLE 3. HR (95% CI) of Self-Reported Hypertension According to Intake of Aspirin and Non-Aspirin Analgesic 
Drugs Regular Intake Stratified by Sex, the SUN Study, 1999-2005
 No Yes Total
Men
 Aspirin   
 New cases of HTN, n 323 25 348
  Person-years, n 15 150 644 15 794
  Age adjusted, HR (95% CI) 1 (Ref) 1.29 (0.85-1.95) 
  Multivariate, HRa (95% IC) 1 (Ref) 1.42 (0.94-2.16) 
 Non-aspirin analgesics drugs   
  New cases of HTN, n 316 32 348
  Person-years, n 15 077 717 15 794
  Age adjusted, HR (95% CI) 1 (Ref) 1.84 (1.30-2.61) 
  Multivariate, HRa (95% IC) 1 (Ref) 1.96 (1.36-2.84) 
Women   
 Aspirin   
  New cases of HTN, n 184 11 195
  Person-years, n 25 380 760 26 139
  Age adjusted, HR (95% CI) 1 (Ref) 1.58 (0.86-2.92) 
  Multivariate, HRa (95% IC) 1 (Ref) 1.41 (0.76-2.62) 
 Non-aspirin analgesics drugs   
  New cases of HTN, n 170 25 195
  Person-years, n 23 602 2538 26 139
  Age and sex adjusted, HR (95% CI) 1 (Ref) 1.32 (0.88-1.99) 
  Multivariate, HRa (95% IC) 1 (Ref) 1.39 (0.91-2.12) 
CI indicates confidence interval; HR, hazard ratio; HTN, hypertension.
aAnalysis adjusted for age (continous), baseline BMI (continuous), leisure-time physical activity (total METs as continuous), alcohol intake (continuous), family history of 
hypertension (binary), self-reported hypercholesterolemia (binary), smoking (current and past smokers versus never smokers), energy adjusted sodium (quartiles), olive oil 
(quartiles), fruit (quartiles), vegetable (quartiles), and low-fat dairy consumption (quartiles).
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responsible for one of the most important NSAIDs 
side-effects: gastritis. COX-2 inhibition reduces 
prostaglandin synthesis and is related to the anti-
inflammatory, analgesic, and antipyretic effects 
of aspirin and other non-selective NSAIDs. COX-
2 inhibition may also be the pathway through 
which aspirin may increase the BP levels. First, 
through prostacyclin (PGI2) reduction that 
increases in turn systemic vascular resistance due to 
unopposed vasoconstriction of angiotensin II and 
catecholamines, and that also increases renal vascular 
resistance with reduced natriuresis and sodium and 
water retention.4,27 Second, through prostaglandin 
E2 reduction which may reduce natriuresis by 30%-
50%, especially in patients with chronic kidney disease 
(a potential conditions in individuals taking COX 
inhibitors chronically).28-31 Finally, some authors 
propose inhibition of aldosterone metabolism with 
subsequent hyperaldosteronism, as a potential 
mechanism for increased BP in aspirin users.32 On 
the other hand, acetaminophen blocks the COX 
enzyme at its peroxidase rather than cyclooxygenase 
catalytic site, and therefore it has different tissue 
specificity and less anti-inflammatory and platelet 
function inhibitory effect.33
There are some limitations in our study. First 
of all, the small number of events might lead to 
unstable models. Secondly, our outcome is self-
reported. Abundant evidence, however, indicates 
that self-reported information about HTN diagnosis 
is valid for epidemiological studies,34 particularly 
among highly educated participants.35 Given the 
high educational level of our participants and 
the universal health care access in the Spanish 
population, we can assume a high validity of self-
reported HTN diagnosis. Finally, considering 
medical diagnosis of HTN as the outcome instead of 
using single BP measurements decreases the chances 
of finding false positives. In fact, in a validation 
study conducted in a randomly selected subsample 
of our cohort, we observed acceptable positive and 
negative predictive values for self-reported medical 
diagnoses of hypertension, even when our gold 
standard, which was a repeated direct measurement, 
missed true cases of hypertension.15 Nevertheless, 
some degree of information bias is likely to exist. 
This could be an important problem if those who 
take aspirin or non-aspirin analgesic drugs more 
often, receive closer medical attention, since it would 
be easier for them to be diagnosed as hypertensives 
in comparison to those who do not take these drugs. 
We acknowledge the possibility of this bias, given 
that our estimates for the HR were not very large. 
Thirdly, residual or unmeasured confounding could 
explain the observed association. Those who do 
not take aspirin and non-aspirin analgesic drugs 
may have an overall healthier lifestyle. However, 
hypertensive therapy.21 Some other cross-over trials 
have assessed whether aspirin may counteract the 
effect of anti-hypertensive drugs on BP. So far, no 
interaction has been found, though the number of 
patients involved in these studies was very small (less 
than 19 patients).22,23 On the other hand, Hermida 
et al reported an inverse association between aspirin 
intake (100 mg/day) given before bed-time and mean 
24 hour BP levels (-6/-4 mm Hg reduction of systolic 
BP/ diastolic BP)10 especially in non-dippers.11 They 
attributed this difference in the circadian variations 
to factors mediating BP control, mainly plasma 
renin activity, angiotensin II and catecholamines. In 
this sense, another trial reported a reduction of 24-h 
ambulatory BP monitoring (systolic BP, -5.7 [2.6] 
mm Hg; P=.008; DBP, -3.8 [1.7] mm Hg; P=.014) 
in hypertensive patients with hypercholesterolemia 
taking antihypertensive medication, statins 
and aspirin (intervention group) compared to 
antihypertensive medication and statins alone 
(control group).24
Two meta-analyses assessing the association of 
aspirin and other NSAIDs with BP levels have been 
published. The first meta-analysis found that among 
a total of 771 participants, NSAIDs increased mean 
blood pressure by 5 mm Hg overall (95% CI, 1.2-
8.7).25 However, the effect was largely limited to 
hypertensive participants receiving antihypertensive 
therapy. Regarding aspirin treatment, they included 
8 trials with a total of 105 hypertensive individuals 
taking ≥1.5 g daily, and found no significant 
association.25 The second meta-analysis found a 
3 mm Hg increase in mean blood pressure with 
NSAIDs that was also limited to participants with 
preexisting hypertension.26 In addition, among the 
different NSAIDs, only indomethacin and naproxen 
were associated with increased blood pressure, 
while ibuprofen and sulindac, were not. Regarding 
specifically aspirin, the meta-analysis included 14 
normotensive and 39 hypertensive individuals taking 
also ≥1.5 g daily, finding an increase of mean BP of 
0.61 mm Hg before adjusting for salt intake, and a 
reduction of 1.62 mm Hg in the normotensive group 
and 1.76 mm Hg in the hypertensive group, after 
adjustment for salt intake. The main limitation of 
both meta-analyses is the reduced number of studies 
and subjects included.
Several mechanisms could explain the observed 
association between aspirin or NSAIDs and 
incident HTN. The most widely proposed and 
accepted mechanism is blockage of cyclooxygenase 
(COX) enzymes.4,27 COX-1 is related to normal cell 
function, like protective gastric mucosa secretion in 
the stomach, salt and water handling in the kidney 
or platelet and endothelium normal function. COX-
2 is more related to inflammatory states, manifested 
with pain, heat, and swelling. COX-1 inhibition is 
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although we cannot rule out the existence of 
unmeasured confounders, we adjusted our analysis 
for the most important known risk factors for 
hypertension and other lifestyle variables such as 
smoking, which could act as markers of general 
lifestyle. Additional analyses including possible 
indications, or contraindications, for NSAID use 
did not greatly impact our estimates. Even after 
adjusting for other analgesics (non-aspirin analgesics 
in the analysis of aspirin, and aspirin in the analysis 
of non-aspirin analgesics) the association remained. 
Although we validated most of the information in 
the questionnaires,18-20 sodium intake is not easily 
measured with food-frequency questionnaires and 
could partially explain the observed association. 
An added limitation is therefore the lack of sodium 
measurement through 24 hours urine collection. 
Finally, we also face the limited information on 
the exposure, since more detailed information on 
drug dosage and type of drug, etc, would have been 
useful especially in relation to a possible dose-effect 
gradient.
CONCLUSIONS
In conclusion, regular use of aspirin or other 
non-aspirin analgesic drugs could be associated 
with incident HTN in a Spanish group of university 
graduates. Further studies are warranted.
ACKNOWLEDGMENTS
We are indebted to the participants of the 
SUN project for their continued cooperation and 
participation. We also thank others members of the 
SUN study group including: M Segui-Gomez, J de 
Irala, JA Martinez, A Marti, M Serrano-Martinez, 
F Guillen-Grima, C de la Fuente-Arrillaga, JF 
Basterra-Gortari, Z Vazquez, S Benito, A Tortosa, 
University of Navarra; M Delgado-Rodriguez, 
University of Jaen; J Llorca, University of 
Cantabria; E Smyth, University of Santiago de 
Compostela; A Sanchez-Villegas, University of Las 
Palmas; I Marques-Lopes, University of Saragossa; 
and CN Lopez, Harvard University. We thank the 
members of the Department of Nutrition of the 
Harvard School of Public Health (A Ascherio, FB 
Hu, WC Willett) who helped us to design the SUN 
project. We also thank Prof Santidrian for sharing 
his wisdom with all of us, and La Caixa Foundation 
for their support to the main author.
REFERENCES
1. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of 
blood-pressure-related disease, 2001. Lancet. 2008;371:1513-8.
Document downloaded from http://www.revespcardiol.org, day 02/06/2012. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
Beunza JJ et al. Aspirin and Non-Aspirin Analgesic Use and Hypertension
 Rev Esp Cardiol. 2010;63(3):286-93  293
20. Martín-Moreno JM, Boyle P, Gorgojo L, Maisonneuve P, 
Fernández-Rodríguez JC, Salvini S, Willett WC. Development 
and validation of a food frequency questionnaire in Spain. Int 
J Epidemiol. 1993 ;22:512-9.
21. Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, 
Warnold I, Wedel H. Low-dose aspirin does not interfere 
with the blood pressure-lowering effects of antihypertensive 
therapy. J Hypertens. 2002;20:1015-22.
22. Polonia J, Boaventura I, Gama G, Camoes I, Bernardo F, 
Andrade P, et al. Influence of non-steroidal anti-inflammatory 
drugs on renal function and 24h ambulatory blood pressure-
reducing effects of enalapril and nifedipine gastrointestinal 
therapeutic system in hypertensive patients. J Hypertens. 
1995;13:925-31.
23. Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA. 
Effect of aspirin on blood pressure in hypertensive patients 
taking enalapril or losartan. Am J Hypertens. 1999;12:784-9.
24. Magen E, Viskoper JR, Mishal J, Priluk R, London D, Yosefy 
C. Effects of low-dose aspirin on blood pressure and endothelial 
function of treated hypertensive hypercholesterolaemic 
subjects. J Hum Hypertens. 2005;19:667-73.
25. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-
inflammatory drugs affect blood pressure? A meta-analysis. 
Ann Intern Med. 1994;121:289-300.
26 Pope JE, Anderson JJ. A meta-analysis of the effects of 
nonsteroideal anti-inflammatory drugs on blood pressure. 
Arch Intern Med. 1993;153:477-84.
27. Mulkerrin EC, Clark BA, Epstein FH. Increased salt retention 
and hypertension from non-steroidal agents in the elderly. 
QJM. 1997;90:411-5.
28. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on 
renal function: focus on cyclooxygenase-2-selective inhibition. 
Am J Med. 1999;107:65S-70S.
29. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, 
Morrow JD, et al. Opposite effects of cyclooxygenase-1 and -2 
activity on the pressor response to angiotensin II. J Clin Invest. 
2002;110:61-9.
30. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory 
drugs: physiologic foundations and clinical implications. Am J 
Med. 1999;106:13S-24S.
31. Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, 
Verburg KM, et al. Effects of celecoxib and naproxen on renal 
function in the elderly. Arch Intern Med. 2000;160:1465-70.
32. Knights KM, Mangoni AA, Miners JO. Non-selective 
nonsteroidal anti-inflammatory drugs and cardiovascular 
events: is aldosterone the silent partner in crime? Br J Clin 
Pharmacol. 2006;61:738-40.
33. Aronoff DM, Oates JA, Boutaud O. New insights into the 
mechanism of action of acetaminophen: Its clinical pharmacologic 
characteristics reflect its inhibition of the two prostaglandin H2 
synthases. Clin Pharmacol Ther. 2006;79:9-19.
34. Tormo MJ, Navarro C, Chirlaque MD, Barber X. Validation of 
self diagnosis of high blood pressure in a sample of the Spanish 
EPIC cohort: overall agreement and predictive values. EPIC 
Group of Spain. J Epidemiol Community Health. 2000;54:221-
6.
35. Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson 
L, Rosner B, et al. Validation of questionnaire information on 
risk factors and disease outcomes in a prospective cohort study 
of women. Am J Epidemiol. 1986;123:894-900.
Document downloaded from http://www.revespcardiol.org, day 02/06/2012. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.
